Innoviva Inc

INVANASDAQ · USD
20.72USD+0.48 (+2.38%)
957

Innoviva Inc (INVA) Option Chain

As of September 23, 2026, Innoviva Inc is trading at $20.72, a +2.38% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 59.8%. IV Rank is 58%.

Read more

Tracking the INVA option chain helps you see every strike and expiry on Innoviva Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Innoviva Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of INVA options activity at a glance. Use our scanner to monitor the INVA option chain in real time and filter for the INVA options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For INVA stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the INVA option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where INVA stock options are being actively traded and where they are not.

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.

The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Innoviva Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen INVA options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of INVA stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile67.46% Elevated
  • Market cap (M$)1,462
  • 52 weeks high-19.49%
  • 52 weeks low22.52%
  • Analyst recommendationBuy
    1.80
  • Target price$35.00
    68.92% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-04
  • P/E4.93
  • Future P/E8.95
  • EPS (ttm)4.10
  • EPS growth next 5 years-15.80%

As of September 23, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
2.55000.185.723.808.0015.00-25.89—3.800.003.800097.45
17.94000.013.221.355.1017.50-13.54—1.400.001.400082.06
49.12801.280.72—2.0020.00-1.19—1.600.001.600050.88
77.874000.750.00—0.7522.50+11.170.504.901.780.920022.13
92.98001.150.00—1.1525.00+23.522.206.404.280.02007.02

As of September 23, 2026

Scan the full option chain in one place

Browse the full INVA option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial